<DOC>
	<DOCNO>NCT00536588</DOCNO>
	<brief_summary>The purpose first-in-human study determine safety tolerability SCH 721015 subject transitional cell carcinoma bladder .</brief_summary>
	<brief_title>A Safety Tolerability Study SCH 721015 Patients With Transitional Cell Carcinoma Bladder ( Study P03816 )</brief_title>
	<detailed_description>A nonrandomized , open-label , rising-dose , parallel-group , multi-center study SCH 721015 patient papillary bladder cancer , carcinoma situ refractory Bacillus Calmette-Guerin . Subjects receive single intravesical administration SCH 721015 SCH 209702 total volume 75 mL 1-hour dwell time . Subjects 3 month post administration demonstrate complete response ( CR cystoscopy/biopsy cytology ) experience dose-limiting toxicity allow receive second intravesical administration dose level .</detailed_description>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Histologically proven recurrent transitional cell carcinoma bladder , Stage Tis , Ta . Patients recurrent T1 disease wish cystectomy . Subjects must fail least two prior course BCG without recombinant interferon alpha administration . At least 3 month must pass since last intravesical treatment bladder carcinoma . Subjects must 18 year age older . Life expectancy least 3 month . Adequate performance status ( Karnofsky score &gt; =70 % ) . Adequate laboratory value . Suspected hypersensitivity interferon alpha . Subjects organ transplant . Any known preexisting medical condition could interfere subject 's participation completion study : History psychosis presence poorly control depression ; CNS trauma active seizure disorder require medication ; Significant cardiovascular dysfunction within past 6 month include symptomatic cardiac ischemia , arrhythmia congestive heart failure require hospitalization emergency room visit within last 3 month ; Poorly control diabetes mellitus ( HbA1C &gt; 10.0 % ) ; Unstable chronic pulmonary disease require hospitalization emergency room visit within last 3 month ; Immunologically mediate disease ( eg , rheumatoid arthritis , autoimmune hepatitis , immune mediate glomerulonephritis ) . History clinically significant local systemic infectious disease within 4 week prior initial treatment administration . Untreated bladder infection . Positive hepatitis BsAg HIV Ab hepatitis C. Immunosuppressive therapy within last 3 month . BCG therapy intravesical therapy within 3 month . Traumatic catheterization within 1 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>